Last reviewed · How we verify

Colchicine (for 6 months)

Azienda Sanitaria Locale 3, Torino · Phase 3 active Small molecule

Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators.

Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators. Used for Acute gout flares, Gout prophylaxis, Familial Mediterranean fever.

At a glance

Generic nameColchicine (for 6 months)
SponsorAzienda Sanitaria Locale 3, Torino
Drug classMicrotubule inhibitor / Anti-inflammatory agent
TargetTubulin (alpha and beta subunits)
ModalitySmall molecule
Therapeutic areaImmunology / Cardiovascular / Rheumatology
PhasePhase 3

Mechanism of action

Colchicine disrupts microtubule dynamics, which impairs the movement and activation of neutrophils and other immune cells. This leads to decreased secretion of pro-inflammatory cytokines and chemokines, reducing the inflammatory cascade. The drug has been used for decades in gout and is being investigated for its anti-inflammatory effects in various cardiovascular and inflammatory conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results